RHBDL1

Across TCGA pan-cancer cohorts, RHBDL1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RHBDL1 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher RHBDL1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RHBDL1 expression acts as an unfavorable survival marker.

KICH, LUAD, and UCEC are the cancer types where RHBDL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LUAD	OS	Median	All	0.323	0.834	.003	12	view →
UCEC	OS	Median	III,IV	0.061	0.588	.018	12	view →
KIRP	DFS	Median	All	0.218	0.613	.012	4	view →
GBM	OS	Median	All	0.089	0.415	.021	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RHBDL1–KICH (DFS)

Open the KICH breakdown →